Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps

Why did Apple’s COO retire suddenly? How will Trump's 50% tariffs impact US copper prices? What triggered NVIDIA's $4 trillion market cap milestone? How will new tariffs affect global trade dynamics? Why is Meta increasing investment in AI technologies? What impact will rising home insurance rates have in Illinois? How are AI tools driving Microsoft’s recent job cuts?

Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps

benzinga.com/news/health-care/25/07/46329274/kazia-reports-over-50-cancer-cell-reduction-in-early-data-from-breast-cancer-trial-stock-jumps

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of…

This story appeared on benzinga.com, 2025-07-09 18:47:12.